April 2024
1. LI X, Ge Z, Kan J, Anjum M, et al
   Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial.
   Lancet. 2024 Apr 5:S0140-6736(24)00282-4. doi: 10.1016/S0140-6736(24)00282.
   

   >> Share

   
   
2. DEN DEKKER WK
   Is intravascular imaging the future of percutaneous coronary intervention?
   Lancet. 2024 Apr 5:S0140-6736(24)00430-6. doi: 10.1016/S0140-6736(24)00430.
   

   >> Share

   
   
3. GE Z, Kan J, Gao X, Raza A, et al
   Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
   Lancet. 2024 Apr 5:S0140-6736(24)00473-2. doi: 10.1016/S0140-6736(24)00473.
   

   >> Share

   
   
4. STEINER-GAGER GM, Siller-Matula JM
   Abbreviated dual antiplatelet therapy after acute coronary syndrome.
   Lancet. 2024 Apr 5:S0140-6736(24)00586-5. doi: 10.1016/S0140-6736(24)00586.
   

   >> Share

   
   
5. PARK SJ, Ahn JM, Kang DY, Yun SC, et al
   Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
   Lancet. 2024 Apr 4:S0140-6736(24)00413-6. doi: 10.1016/S0140-6736(24)00413.
   

   >> Share

   
   
6. BOROVAC JA
   Percutaneous coronary intervention for non-obstructive vulnerable plaques.
   Lancet. 2024 Apr 4:S0140-6736(24)00488-4. doi: 10.1016/S0140-6736(24)00488.
   

   >> Share

   
   March 2024
7. RIDKER PM, Bhatt DL, Nissen SE
   Inflammation, infection, and cardiovascular risk - Authors' reply.
   Lancet. 2024;403:1025-1026.
   

   >> Share

   
   
8. SHARMA S, Sharma R
   Inflammation, infection, and cardiovascular risk.
   Lancet. 2024;403:1024-1025.
   

   >> Share

   
   
9. GOLDMAN M, Bondue A, Cogan E
   Inflammation, infection, and cardiovascular risk.
   Lancet. 2024;403:1023.
   

   >> Share

   
   
10. GOLDSTEIN MR, Mascitelli L
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1023-1024.
    

    >> Share

    
    
11. DROZD M, Cubbon R
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1022-1023.
    

    >> Share

    
    
12. PAREEK A, Chandurkar N, Naidu K, Raut V, et al
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1022.
    

    >> Share

    
    
13. STRANDBERG TE, Kovanen PT, Gylling H
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1021.
    

    >> Share

    
    
14. LIN GM, Huang WC, Han CL
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1021-1022.
    

    >> Share

    
    February 2024
15. LEE ZS, Ryan N
    Intravascular imaging in percutaneous coronary intervention.
    Lancet. 2024 Feb 21:S0140-6736(23)02686-7. doi: 10.1016/S0140-6736(23)02686.
    

    >> Share

    
    
16. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
    Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
    Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
    

    >> Share

    
    December 2023
17. JIMENEZ DIAZ VA, Iniguez Romo A
    Intracoronary artery visualisation of crystalline sirolimus deposits after drug-coated balloon angioplasty for acute coronary syndrome.
    Lancet. 2023;402:2111-2112.
    

    >> Share

    
    November 2023
18. ZAMAN M, de Vale ML, Coultas C, Goff L, et al
    Factors affecting the delivery of community-based salon interventions to prevent cardiovascular disease and breast cancer among ethnically diverse women in South London: a concept-mapping approach.
    Lancet. 2023;402 Suppl 1:S96.
    

    >> Share

    
    
19. KHAN Y, Verhaeghe N, Devleesschauwer B, Cavillot L, et al
    Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.
    Lancet. 2023;402 Suppl 1:S61.
    

    >> Share

    
    October 2023
20. IGLESIAS JF, Roffi M, Losdat S, Muller O, et al
    Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial.
    Lancet. 2023 Oct 25:S0140-6736(23)02197-9. doi: 10.1016/S0140-6736(23)02197.
    

    >> Share

    
    
21. BUITEN RA, Ploumen EH
    Drug-eluting stents for ST-segment elevation myocardial infarction: extending the biodegradable versus durable polymer debate.
    Lancet. 2023 Oct 25:S0140-6736(23)02297-3. doi: 10.1016/S0140-6736(23)02297.
    

    >> Share

    
    
22. ZEYMER U, Freund A, Hochadel M, Ostadal P, et al
    Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials.
    Lancet. 2023;402:1338-1346.
    

    >> Share

    
    
23. PATTERSON T, Perkins GD, Perkins A, Clayton T, et al
    Expedited transfer to a cardiac arrest centre for non-ST-elevation out-of-hospital cardiac arrest (ARREST): a UK prospective, multicentre, parallel, randomised clinical trial.
    Lancet. 2023;402:1329-1337.
    

    >> Share

    
    September 2023
24. HEYMANS S, Lakdawala NK, Tschope C, Klingel K, et al
    Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches.
    Lancet. 2023;402:998-1011.
    

    >> Share

    
    August 2023
25. DILETTI R, den Dekker WK, Elscot JJ, Boersma E, et al
    Complete revascularisation in patients with acute coronary syndrome - Authors' reply.
    Lancet. 2023;402:612.
    

    >> Share

    
    
26. DE CARLO M, Petronio AS, De Caterina R
    Complete revascularisation in patients with acute coronary syndrome.
    Lancet. 2023;402:611-612.
    

    >> Share

    
    
27. XU X, Zhu H, Chen T, Cai L, et al
    Complete revascularisation in patients with acute coronary syndrome.
    Lancet. 2023;402:611.
    

    >> Share

    
    
28. SHAH R
    Complete revascularisation in patients with acute coronary syndrome.
    Lancet. 2023;402:610-611.
    

    >> Share

    
    July 2023
29. JEE J
    Machine learning-based markers for CAD.
    Lancet. 2023;402:183.
    

    >> Share

    
    
30. ELLIOTT A, Pirruccello JP
    Machine learning-based markers for CAD.
    Lancet. 2023;402:182-183.
    

    >> Share

    
    
31. YU L
    Machine learning-based markers for CAD.
    Lancet. 2023;402:182.
    

    >> Share

    
    April 2023
32. GAUDINO M, Andreotti F, Kimura T
    Current concepts in coronary artery revascularisation.
    Lancet. 2023 Apr 27:S0140-6736(23)00459-2. doi: 10.1016/S0140-6736(23)00459.
    

    >> Share

    
    March 2023
33. DILETTI R, den Dekker WK, Bennett J, Schotborgh CE, et al
    Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial.
    Lancet. 2023 Mar 3:S0140-6736(23)00351-3. doi: 10.1016/S0140-6736(23)00351.
    

    >> Share

    
    
34. RIDKER PM, Bhatt DL, Pradhan AD, Glynn RJ, et al
    Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.
    Lancet. 2023 Mar 3:S0140-6736(23)00215-5. doi: 10.1016/S0140-6736(23)00215.
    

    >> Share

    
    
35. TARDIF JC, Samuel M
    Inflammation contributes to cardiovascular risk in patients receiving statin therapy.
    Lancet. 2023 Mar 3:S0140-6736(23)00454-3. doi: 10.1016/S0140-6736(23)00454.
    

    >> Share

    
    
36. PUSTJENS TFS, Vriesendorp PA, Van't Hof AWJ
    Revascularisation in acute coronary syndromes: change in practice?
    Lancet. 2023 Mar 3:S0140-6736(23)00403-8. doi: 10.1016/S0140-6736(23)00403.
    

    >> Share

    
    
37. HE J, Ouyang N, Guo X, Sun G, et al
    Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    Lancet. 2023 Mar 2:S0140-6736(22)02603-4. doi: 10.1016/S0140-6736(22)02603.
    

    >> Share

    
    
38. YAN LL, Karmacharya BM
    Improving cardiovascular health in rural China and beyond.
    Lancet. 2023 Mar 2:S0140-6736(23)00092-2. doi: 10.1016/S0140-6736(23)00092.
    

    >> Share

    
    February 2023
39. WANG Y, Li S, Pan Y, Li H, et al
    Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
    Lancet. 2023 Feb 8:S0140-6736(22)02600-9. doi: 10.1016/S0140-6736(22)02600.
    

    >> Share

    
    
40. MENON BK, Singh N, Sylaja PN
    Tenecteplase use in patients with acute ischaemic stroke.
    Lancet. 2023 Feb 8:S0140-6736(22)02633-2. doi: 10.1016/S0140-6736(22)02633.
    

    >> Share

    
    January 2023
41. TAWFIQ E, Selak V, Elwood JM, Pylypchuk R, et al
    Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study.
    Lancet. 2023 Jan 23:S0140-6736(22)02405-9. doi: 10.1016/S0140-6736(22)02405.
    

    >> Share

    
    
42. ROSSELLO X
    Cardiovascular risk assessment in survivors of cancer.
    Lancet. 2023 Jan 23:S0140-6736(22)02582-X. doi: 10.1016/S0140-6736(22)02582.
    

    >> Share

    
    
43. WENZL FA, Luscher TF
    Application of a sex-specific GRACE score in practice - Authors' reply.
    Lancet. 2023;401:23.
    

    >> Share

    
    
44. KIMENAI DM, Mills NL
    Application of a sex-specific GRACE score in practice.
    Lancet. 2023;401:22-23.
    

    >> Share

    
    
45. CONRAD N, McMurray JJV
    Cardiovascular risk in systemic autoimmune diseases - Authors' reply.
    Lancet. 2023;401:22.
    

    >> Share

    
    
46. FUNADA S, Luo Y, Nishioka N, Yoshioka T, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21.
    

    >> Share

    
    
47. CAFARO G, Perricone C, Gerli R, Bartoloni E, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21-22.
    

    >> Share

    
    December 2022
48. BATRA P, Khera AV
    Machine learning to assess coronary artery disease status-is it helpful?
    Lancet. 2022 Dec 20:S0140-6736(22)02584-3. doi: 10.1016/S0140-6736(22)02584.
    

    >> Share

    
    
49. FORREST IS, Petrazzini BO, Duffy A, Park JK, et al
    Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts.
    Lancet. 2022 Dec 20:S0140-6736(22)02079-7. doi: 10.1016/S0140-6736(22)02079.
    

    >> Share

    
    November 2022
50. COUGHLAN JJ, Kastrati A
    Bivalirudin in patients with ST-segment elevation myocardial infarction.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02162.
    

    >> Share

    
    
51. LI Y, Liang Z, Qin L, Wang M, et al
    Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)01999.
    

    >> Share

    
    October 2022
52. MACKENZIE IS, Rogers A, Poulter NR, Williams B, et al
    Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.
    Lancet. 2022 Oct 11. pii: S0140-6736(22)01786.
    

    >> Share

    
    
53. MACKENZIE IS, Hawkey CJ, Ford I, Greenlaw N, et al
    Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Lancet. 2022;400:1195-1205.
    

    >> Share

    
    
54. NI AINLE F, Middeldorp S, Le Gal G, Hunt BJ, et al
    Protecting patients during a shortage of thrombolytic agents.
    Lancet. 2022;400:1193-1194.
    

    >> Share

    
    
55. TANAKA A, Node K
    Xanthine oxidase inhibition for cardiovascular disease prevention.
    Lancet. 2022;400:1172-1173.
    

    >> Share

    
    September 2022
56. WALLI-ATTAEI M, Rosengren A, Rangarajan S, Breet Y, et al
    Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study.
    Lancet. 2022;400:811-821.
    

    >> Share

    
    
57. MANFRINI O, Bugiardini R
    Behavioural risk factors and cardiovascular disease: are women at higher risk?
    Lancet. 2022;400:788-789.
    

    >> Share

    
    August 2022
58. WENZL FA, Kraler S, Ambler G, Weston C, et al
    Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01483.
    

    >> Share

    
    
59. DE MIGUEL-BALSA E
    Risk stratification and health inequalities in women with acute coronary syndrome: time to move on.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01607.
    

    >> Share

    
    
60. CONRAD N, Verbeke G, Molenberghs G, Goetschalckx L, et al
    Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01349.
    

    >> Share

    
    July 2022
61. KIM BK, Hong SJ, Lee YJ, Hong SJ, et al
    Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
    Lancet. 2022 Jul 18. pii: S0140-6736(22)00916.
    

    >> Share

    
    June 2022
62. SANDSET EC, Tsvigoulis G
    Tenecteplase for acute ischaemic stroke.
    Lancet. 2022 Jun 28. pii: S0140-6736(22)01107.
    

    >> Share

    
    
63. MENON BK, Buck BH, Singh N, Deschaintre Y, et al
    Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
    Lancet. 2022 Jun 28. pii: S0140-6736(22)01054.
    

    >> Share

    
    May 2022
64. DELGADO-LISTA J, Alcala-Diaz JF, Torres-Pena JD, Quintana-Navarro GM, et al
    Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial.
    Lancet. 2022 May 4. pii: S0140-6736(22)00122.
    

    >> Share

    
    April 2022
65. BERGMARK BA, Mathenge N, Merlini PA, Lawrence-Wright MB, et al
    Acute coronary syndromes.
    Lancet. 2022;399:1347-1358.
    

    >> Share

    
    February 2022
66. BODEN WE, Kaski JC, Al-Lamee R, Weintraub WS, et al
    What constitutes an appropriate empirical trial of antianginal therapy in patients with stable angina before referral for revascularisation?
    Lancet. 2022;399:691-694.
    

    >> Share

    
    November 2021
67. CALDEIRA D, Pinto FJ
    COVID-19 and myocardial infarction.
    Lancet. 2021;398:1963-1964.
    

    >> Share

    
    
68. KATSOULARIS I, Fonseca-Rodriguez O, Farrington P, Lindmark K, et al
    COVID-19 and myocardial infarction - Authors' reply.
    Lancet. 2021;398:1964.
    

    >> Share

    
    
69. SABATINE MS, Bergmark BA, Murphy SA, O'Gara PT, et al
    Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis.
    Lancet. 2021 Nov 12. pii: S0140-6736(21)02334.
    

    >> Share

    
    
70. MEHRAN R, Owen R, Chiarito M, Baber U, et al
    A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry.
    Lancet. 2021 Nov 12. pii: S0140-6736(21)02326.
    

    >> Share

    
    
71. BELLEY-COTE EP, Devereaux PJ
    PCI versus CABG for left main coronary artery disease: is the jury still out?
    Lancet. 2021 Nov 12. pii: S0140-6736(21)02491.
    

    >> Share

    
    
72. KANG J, Koo BK, Park KW, Shin ES, et al
    Aspirin versus clopidogrel after percutaneous coronary intervention - Authors' reply.
    Lancet. 2021;398:1685-1686.
    

    >> Share

    
    
73. PAREEK M, Byrne C
    Aspirin versus clopidogrel after percutaneous coronary intervention.
    Lancet. 2021;398:1685.
    

    >> Share

    
    
74. BYRNE RA, McGovern L
    Angiography-derived quantitative flow ratio guidance of coronary intervention: measure twice, cut once.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02397.
    

    >> Share

    
    
75. XU B, Tu S, Song L, Jin Z, et al
    Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02248.
    

    >> Share

    
    October 2021
76. DEL PRATO S, Kahn SE, Pavo I, Weerakkody GJ, et al
    Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Lancet. 2021 Oct 18. pii: S0140-6736(21)02188.
    

    >> Share

    
    
77. KIM CJ, Park MW, Kim MC, Choo EH, et al
    Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised tr
    Lancet. 2021;398:1305-1316.
    

    >> Share

    
    
78. TSAMPASIAN V, Maart C, Vassiliou VS, Garg P, et al
    Mitral valve disease in sarcoidosis diagnosed by cardiovascular magnetic resonance.
    Lancet. 2021;398:1358.
    

    >> Share

    
    September 2021
79. PINTO FJ, Pineiro D, Banerjee A, Perel P, et al
    World Heart Day 2021: COVID-19, digital health, and tackling cardiovascular disease.
    Lancet. 2021 Sep 28. pii: S0140-6736(21)02144.
    

    >> Share

    
    
80. 
    Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Lancet. 2021 Sep 7. pii: S0140-6736(21)01122.
    

    >> Share

    
    March 2021
81. LONNEBAKKEN MT
    The risk of no risk in STEMI.
    Lancet. 2021;397:1039-1040.
    

    >> Share

    
    
82. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    

    >> Share

    
    February 2021
83. TAKAHASHI K, van Klaveren D, Steyerberg EW, Onuma Y, et al
    Concerns with the new SYNTAX score - Authors' reply.
    Lancet. 2021;397:795-796.
    

    >> Share

    
    
84. FREEMANTLE N, Pagano D
    Concerns with the new SYNTAX score.
    Lancet. 2021;397:795.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share